Lead Product(s) : Urinastatin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bharat Serums to assess sepsis drug Ulinastatin for Covid-19
Details : The trial will involve approximately 120 patients who have mild to moderate symptoms of acute ARDS. The drug is expected to improve recovery time and also mitigate mortality rates.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2020
Lead Product(s) : Urinastatin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Urinastatin
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : The First Affiliated Hospital of Guangzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 09, 2016
Lead Product(s) : Urinastatin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : The First Affiliated Hospital of Guangzhou Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Urinastatin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase IV
Sponsor : Techpool Bio-Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2016
Lead Product(s) : Urinastatin
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase IV
Sponsor : Techpool Bio-Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Urinastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Shanghai Children's Medical Center | Guangzhou Women and Children's Medical Center | Guangzhou General Hospital of Guangzhou Military Command | Nanjing Children's Hospital | Children's Hospital of Fudan University
Deal Size : Inapplicable
Deal Type : Inapplicable
Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 19, 2015
Lead Product(s) : Urinastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Shanghai Children's Medical Center | Guangzhou Women and Children's Medical Center | Guangzhou General Hospital of Guangzhou Military Command | Nanjing Children's Hospital | Children's Hospital of Fudan University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Urinastatin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase IV
Sponsor : Peking Union Medical College Hospital | Wuhan Union Hospital | First Clinical College of Harbin Medical University | The First Affiliated Hospital with Nanjing Medical University | West China Hospital | First Affiliated Hospital, Sun Yat-Sen University
Deal Size : Inapplicable
Deal Type : Inapplicable
Ulinastatin in Severe Acute Pancreatitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2010
Lead Product(s) : Urinastatin
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase IV
Sponsor : Peking Union Medical College Hospital | Wuhan Union Hospital | First Clinical College of Harbin Medical University | The First Affiliated Hospital with Nanjing Medical University | West China Hospital | First Affiliated Hospital, Sun Yat-Sen University
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
